-
A multicenter non-inferiority open-labeled randomized controlled trial of oral amoxicillin-clavulanate (50 mg/kg/day divided 3 times a day for 10 days) compared to initial parenteral treatment with ceftriaxone (50 mg/kg/day as a single daily dose for 3 days) followed by oral amoxicillin-clavulanate (for 7 days) for children < 6 years of age with acute pyelonephritis and no anatomic urogenital tract abnormalities was conducted from 2000 to 2004 among 502 children 1 month to 7 years of age in 28 primary care practices in northern Italy.
-
Synopsis: A large primary care pediatric study of recurrent urinary tract infections found a 12% per year recurrence rate with risk factors being white race, age 3-5 years, and grade 4-5 vesicoureteral reflux. Antimicrobial prophylaxis did not reduce the risk for recurrence but was associated with increased risk of recurrent infection caused by resistant organisms.
-
There is no proven therapy for infection due to the mosquito-borne flavivirus West Nile Virus, introduced to a fully susceptible U.S. population in 1999.
-
Guidelines for this years influenza season are now available, with important recommendations to hospitals and clinics.
-
-
Patients receiving a probiotic yogurt drink were protected from antibiotic associated bacteria.
-
Fully 95% of serum thyrotropin (TSH) measurements were normal in screening tests ordered by primary care physicians. Half of abnormal TSH labs became normal upon repeat measurement. If the initial TSH result was normal, there was only a 2% chance it would become abnormal within 5 years.
-
Currently prevailing scientific opinion denies any relationship between diet and acne: teenagers throughout the land rejoice over their freedom to eat as much pizza, popcorn, chocolate, and soda (the four food groups from age 14-20) as they wish. But the last word may not yet be in.
-
12-lead ECG obtained from an 81-year old woman with new onset heart failure, but no chest pain.
-
Adding an anticoagulant to aspirin is of no value in patients with peripheral artery disease, older adults with coronary disease benefit from aggressive statin therapy, simvastatin may reduce the risk of dementia and Parkinson's disease by as much as 50%, MiraLax is safe for long-term use in patients with chronic constipation, the FDA green-lights Avandia, brings back Zelnorm for limited use, and recommends approving Evista for breast cancer prevention.
